Trademark: 86300720
Word
NK VUE
Status
Registered
Status Code
702
Status Date
Saturday, February 4, 2023
Serial Number
86300720
Registration Number
4993881
Registration Date
Tuesday, July 5, 2016
Mark Type
4000
Filing Date
Wednesday, June 4, 2014
Published for Opposition
Tuesday, August 18, 2015

Trademark Owner History
NKMAX CO., LTD. -
ATGen Co., Ltd. - Original Registrant

Classifications
5 diagnostic kits for medical diagnostic use, namely, kits consisting primarily of monoclonal antibodies and/or recombinant proteins, RNA, DNA for use in disease diagnosis, screening, monitoring, prognosis, and immune status; diagnostic activators in the nature of proteins for use in diagnostic kits for disease diagnosis, screening, monitoring, prognosis, and immune status; diagnostic preparations for medical diagnostic use; diagnostic reagents for medical diagnostic use
1 NK cell activation testing kits containing peptide substrates used in analyzing and detecting certain toxins for clinical, research or medical laboratory use; diagnostic kits for clinical laboratory use, namely, kits consisting primarily of monoclonal antibodies and/or recombinant proteins, RNA, DNA for use in disease diagnosis, screening, monitoring, prognosis, and immune status; diagnostic kits for medical laboratory use, namely, kits consisting primarily of monoclonal antibodies and/or recombinant proteins, RNA, DNA for use in disease diagnosis, screening, monitoring, prognosis, and immune status; diagnostic kits for medical research use, namely, kits consisting primarily of (monoclonal antibodies and/or recombinant proteins, RNA, DNA for use in disease diagnosis, screening, monitoring, prognosis, and immune status; diagnostic kits for clinical research use, namely, kits consisting primarily of monoclonal antibodies and/or recombinant proteins, RNA, DNA for use in disease diagnosis, screening, monitoring, prognosis, and immune status; diagnostic preparations for clinical laboratory use and medical laboratory use; diagnostic preparations for clinical research use other than for medical use; diagnostic reagents for clinical laboratory use, medical laboratory use, medical research use and clinical research use
NK VIEW
"NK"

Trademark Events
Feb 4, 2023
Notice Of Acceptance Of Sec. 8 & 15 - E-Mailed
Feb 4, 2023
Registered - Sec. 8 (6-Yr) Accepted & Sec. 15 Ack.
Feb 4, 2023
Case Assigned To Post Registration Paralegal
Aug 3, 2022
Automatic Update Of Assignment Of Ownership
Jul 19, 2022
Teas Section 8 & 15 Received
Jul 5, 2021
Courtesy Reminder - Sec. 8 (6-Yr) E-Mailed
Dec 2, 2016
Teas Change Of Correspondence Received
Jul 5, 2016
Registered-Principal Register
Jun 2, 2016
Notice Of Acceptance Of Statement Of Use E-Mailed
Jun 1, 2016
Allowed Principal Register - Sou Accepted
May 17, 2016
Statement Of Use Processing Complete
Apr 13, 2016
Use Amendment Filed
May 12, 2016
Case Assigned To Intent To Use Paralegal
Apr 13, 2016
Teas Statement Of Use Received
Oct 13, 2015
Noa E-Mailed - Sou Required From Applicant
Aug 18, 2015
Official Gazette Publication Confirmation E-Mailed
Aug 18, 2015
Published For Opposition
Jul 29, 2015
Notification Of Notice Of Publication E-Mailed
Jul 16, 2015
Law Office Publication Review Completed
Jul 1, 2015
Approved For Pub - Principal Register
Jun 24, 2015
Examiner's Amendment Entered
Jun 22, 2015
Notification Of Examiners Amendment E-Mailed
Jun 22, 2015
Examiners Amendment E-Mailed
Jun 22, 2015
Examiners Amendment -Written
Apr 14, 2015
Notification Of Final Refusal Emailed
Apr 14, 2015
Final Refusal E-Mailed
Apr 14, 2015
Final Refusal Written
Mar 18, 2015
Teas/Email Correspondence Entered
Mar 18, 2015
Correspondence Received In Law Office
Mar 17, 2015
Assigned To Lie
Mar 9, 2015
Teas Response To Office Action Received
Sep 22, 2014
Notification Of Non-Final Action E-Mailed
Sep 22, 2014
Non-Final Action E-Mailed
Sep 22, 2014
Non-Final Action Written
Sep 16, 2014
Assigned To Examiner
Jun 18, 2014
Notice Of Pseudo Mark E-Mailed
Jun 17, 2014
New Application Office Supplied Data Entered
Jun 7, 2014
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24